The MULTISITE Study
NAFLD, Obesity, Extracellular Vesicles
About this trial
This is an interventional treatment trial for NAFLD
Eligibility Criteria
Inclusion Criteria: Age 30-60 BMI between 30,0 - 39,9 kg/m2. Signed informed consent. Metabolic syndrome NAFLD Wishes to participate in a weight reduction program. Exclusion Criteria: Diabetes or any significant endocrine, heart, kidney, liver, or malignant disease. Pregnancy, planned pregnancy, or breast-feeding during the trial. Alcohol abuse or abuse of recreational drugs Medical treatment (systemic glucocorticoids, steatosis-inducing drugs, antibiotics up to two months prior to inclusion, or chemotherapy) or participation in clinical trials other than this. Excessive weight loss within the last three months (defined as more than 10 kilograms). Contraindications for MRI and dual energy x-ray absorptiometry (DEXA)scanning. Any medical condition or history thereof or any deviation from normal laboratory values that, in the opinion of the investigator, clinically contraindicates or hinders the completion of the trial procedures.
Sites / Locations
- Aalborg University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
No Intervention
No Intervention
Metabolically unhealthy obese (Intervention group)
Metabolically healthy obese (Comparison group 1)
Healthy normal weight (Comparison group 2)
Obese (BMI: 30.0 - 39.9) participants with non-alcoholic fatty liver disease and metabolic syndrome.
Obese individuals considered metabolically healthy based on them not presenting non-alcoholic fatty liver disease or metabolic syndrome.
Normal weight individuals without non-alcoholic fatty liver disease or metabolic syndrome.